Clinical trials located in

Langen

Langen city is located in Germany. Currently, 11 clinical trials are being conducted in this city.

Langen, located in the Hesse region of Germany, is a city rich in history and culture. Known for its picturesque parks and forests, Langen offers a serene escape amidst nature. The city is home to the German Air Traffic Control, playing a crucial role in the country’s aviation. Langen also boasts a vibrant cultural scene, with the Neue Stadthalle Langen hosting various events. The city’s commitment to environmental sustainability is evident in its extensive cycling paths and green initiatives. With its blend of modernity and tradition, Langen is a unique German city.

  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • Study of the safety and effectiveness of GLSI-100 in patients with HER2-positive breast cancer

    The study concerns the treatment of patients with HER2/neu-positive breast cancer. Treatment will include GLSI-100 immunotherapy and comparison to placebo. GLSI-100 consists of GP2 peptide and GM-CSF, protein substances that are designed to strengthen the body’s immune response, i.e. natural protection against diseases.

    The aim of this study is to determine how effective and safe GLSI-100 therapy is compared to placebo in preventing breast cancer recurrence after standard treatment. The study is aimed at people at high risk of disease recurrence who have completed both preoperative and postoperative therapy based on trastuzumab, a drug used to treat breast cancer.

    The study will assess invasive breast cancer-free survival (i.e. the time from the first dose of the drug to the moment of disease recurrence or death from any cause), invasive disease-free survival (i.e. the time from the first dose of the drug to the moment of any disease recurrence or new cancer), remote disease (i.e. time until disease recurrence in a place other than the breast or death).

    The study also includes an assessment of the participants’ quality of life both at the beginning and over the next 36 months, as well as an analysis of the body’s immune response to treatment.

  • Study of Tobemstomig and supportive medications for patients with advanced or metastatic triple-negative breast cancer

    The clinical trial is for patients with triple-negative breast cancer (TNBC) that is locally advanced, inoperable or metastatic (stage IV) and has not been previously treated. The study compares a new immune therapy, Tobemstomig (RO7247669), in combination with Nab-Paclitaxel, and Pembrolizumab.

    The aim of the study is to assess the effectiveness and safety of the therapy. Patients will be randomly assigned to one of two groups: in the first group, patients will receive Tobemstomig every three weeks and Nab-Paclitaxel for three weeks, followed by a week off. In the second group, patients will receive Pembrolizumab every three weeks and Nab-Paclitaxel for three weeks, followed by a week off. Therapies will be continued until disease progression or for a maximum of 24 months from the start of treatment.

    The study is aimed at adults aged 18 and over who are well enough to be eligible for treatment. The presence of appropriate markers in the tumor tissue is also required. Patients cannot participate in the study if they have ongoing infections, uncontrolled health problems, or are pregnant.

    • Tobemstomig
    • Pembrolizumab
    • nab-Paclitaxel
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Examining the effectiveness of a new medicine for recent heart attack patients

    This trial is focused on a medicine called BI 765845, and it aims to determine its effectiveness for individuals who have experienced a heart attack. The objective is to assess the effectiveness of different quantities of the medicine when administered to these patients. Participation is limited to adults who have recently suffered a heart attack. During the study, some participants will receive the medicine, while others will be administered a placebo. The placebo lacks any medicinal properties. The likelihood of receiving the real medicine is four times greater than receiving the placebo. Over the next three months, participants will be requested to make multiple visits to the study site for heart health assessments. Any side effects will be documented and regularly monitored. The goal is to compare the results between the medicine and the placebo to determine which one is more effective.

    • BI 765845- new potential medication for ST segment-elevation myocardial infarction
  • Study of Dato-DXd and durvalumab in persistent triple-negative breast cancer

    This trial is about testing a combination of new treatments for triple-negative breast cancer which hasn’t fully responded to the first line of treatment. The new treatment includes a drug called Dato-DXd and a known drug called Durvalumab, both administered individually, or as a combination. This is compared to an already established treatment recommended by the doctor. The researchers are mainly interested in delaying the return of the cancer, and if the new drug with or without Durvalumab does a better job at this than the doctor-recommended treatment. Along with this main goal, the trial will also monitor how these treatments affect patients’ routine activities, their well-being, their levels of fatigue, the amount of Dato-DXd and related components present in the body, and any side effects and potential risks associated with these treatments.

    • Dato-DXd
    • Pembrolizumab
    • Capecitabine
    • Durvalumab
  • Dato-DXd versus Standard Chemotherapy in Advanced Triple-negative Breast Cancer Study

    This clinical trial investigates a new treatment, Dato-DXd, compared to standard chemotherapy for patients with triple-negative breast cancer that is locally recurrent, inoperable, or metastatic and not suitable for PD-1/PD-L1 inhibitor therapy. The study, open to adults, aims to assess the treatment’s effectiveness and safety through random assignment to either Dato-DXd or investigator-chosen chemotherapy. The trial seeks 600 participants and involves regular monitoring of health and progression of the disease. It emphasizes patient eligibility based on specific health criteria and the nature of their breast cancer.

    • Eribulin mesylate
    • Dato-DXd
    • Carboplatin
    • nab-Paclitaxel
    • Capecitabine
    • Paclitaxel
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Examining hydroxyurea treatment resistance in people with Polycythemia Vera

    This clinical trial aims to investigate the factors that predict hydroxyurea (HU) treatment failure in adult patients with polycythemia vera. Polycythemia vera is a blood disorder that affects the body’s red blood cells and can lead to life-threatening complications such as blood clots and strokes. HU is a common treatment for the condition, but some patients may develop resistance to the medication. In this open-label, researchers will evaluate HU resistance in patients with polycythemia vera. The study includes three periods: screening, an observation period for HU resistance, and a follow-up period. Eligible participants will receive HU treatment for up to 15 months. The trial aims to enroll 300 adult patients with polycythemia vera.

    • Hydroxyurea

See more clinical trials in other cities in Germany:

.